These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 33161290)

  • 21. ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly.
    Slot RER; Kester MI; Van Harten AC; Jongbloed W; Bouwman FH; Teunissen CE; Scheltens P; van der Flier WM; Veerhuis R
    Neurobiol Aging; 2019 Jul; 79():101-109. PubMed ID: 31029938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial.
    Hanson AJ; Bayer-Carter JL; Green PS; Montine TJ; Wilkinson CW; Baker LD; Watson GS; Bonner LM; Callaghan M; Leverenz JB; Tsai E; Postupna N; Zhang J; Lampe J; Craft S
    JAMA Neurol; 2013 Aug; 70(8):972-80. PubMed ID: 23779114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
    Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
    Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CSF level of β-amyloid peptide predicts mortality in Alzheimer's disease.
    Boumenir A; Cognat E; Sabia S; Hourregue C; Lilamand M; Dugravot A; Bouaziz-Amar E; Laplanche JL; Hugon J; Singh-Manoux A; Paquet C; Dumurgier J
    Alzheimers Res Ther; 2019 Mar; 11(1):29. PubMed ID: 30922415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. White matter hyperintensities mediate the impact of amyloid ß on future freezing of gait in Parkinson's disease.
    Dadar M; Miyasaki J; Duchesne S; Camicioli R
    Parkinsonism Relat Disord; 2021 Apr; 85():95-101. PubMed ID: 33770671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer's disease.
    Wang S; Zhang J; Pan T;
    Neurosci Lett; 2018 Oct; 685():109-113. PubMed ID: 30144541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apolipoprotein E ε4 Allele is Associated With Plasma Amyloid Beta and Amyloid Beta Transporter Levels: A Cross-sectional Study in a Rural Area of Xi'an, China.
    Wei S; Gao L; Jiang Y; Shang S; Chen C; Dang L; Zhao B; Zhang J; Wang J; Huo K; Wang J; Zhang R; Qu Q
    Am J Geriatr Psychiatry; 2020 Feb; 28(2):194-204. PubMed ID: 31350163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.
    Herukka SK; Helisalmi S; Hallikainen M; Tervo S; Soininen H; Pirttilä T
    Neurobiol Aging; 2007 Apr; 28(4):507-14. PubMed ID: 16546302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects.
    Millard SP; Lutz F; Li G; Galasko DR; Farlow MR; Quinn JF; Kaye JA; Leverenz JB; Tsuang D; Yu CE; Peskind ER; Bekris LM
    Neurobiol Aging; 2014 Feb; 35(2):357-64. PubMed ID: 24011543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
    Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
    BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of the apolipoprotein E epsilon4 allele is associated with working memory impairment in Parkinson's disease.
    Tröster AI; Fields JA; Paolo AM; Koller WC
    J Neurol Sci; 2006 Oct; 248(1-2):62-7. PubMed ID: 16769085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic variants in PSEN2 and correlation to CSF β-amyloid42 levels in AD.
    Lebedeva E; Stingl JC; Thal DR; Ghebremedhin E; Strauss J; Özer E; Bertram L; von Einem B; Tumani H; Otto M; Riepe MW; Högel J; Ludolph AC; von Arnim CA
    Neurobiol Aging; 2012 Jan; 33(1):201.e9-18. PubMed ID: 20850903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease.
    Sun X; Dong C; Levin B; Crocco E; Loewenstein D; Zetterberg H; Blennow K; Wright CB;
    Alzheimers Dement; 2016 Nov; 12(11):1159-1166. PubMed ID: 27321472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease.
    Tapiola T; Pirttilä T; Mehta PD; Alafuzofff I; Lehtovirta M; Soininen H
    Neurobiol Aging; 2000; 21(5):735-40. PubMed ID: 11016543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A large ApoE ε4/ε4 homozygous cohort reveals no association with Parkinson's disease.
    Multhammer M; Michels A; Zintl M; Mendoza MC; Klünemann HH
    Acta Neurol Belg; 2014 Mar; 114(1):25-31. PubMed ID: 23794363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the apolipoprotein E ε4 allele on early Parkinson's disease progression.
    Kim R; Park S; Yoo D; Jun JS; Jeon B
    Parkinsonism Relat Disord; 2021 Feb; 83():66-70. PubMed ID: 33484977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease.
    Feldman B; Chapman J; Korczyn AD
    Acta Neurol Scand; 2006 Jan; 113(1):14-7. PubMed ID: 16367893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease.
    Mengel D; Dams J; Ziemek J; Becker J; Balzer-Geldsetzer M; Hilker R; Baudrexel S; Kalbe E; Schmidt N; Witt K; Liepelt-Scarfone I; Gräber S; Petrelli A; Neuser P; Schulte C; Linse K; Storch A; Wittchen HU; Riedel O; Mollenhauer B; Ebentheuer J; Trenkwalder C; Klockgether T; Spottke A; Wüllner U; Schulz JB; Reetz K; Heber IA; Ramirez A; Dodel R
    Parkinsonism Relat Disord; 2016 Aug; 29():112-6. PubMed ID: 27321987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.